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Abbreviations 
ANOVA, analysis of variance; ChAT, choline acetyltransferase; CNS, central nervous system; 
DAT, dopamine transporter; DMSO, dimethylsulphoxide; ENS, enteric nervous system; 
GFAP, glial fibrillary acidic protein; KO, knockout; LB, Lewy-body; LN, Lewy-neurite; MT, 
metallothionein; PB, phosphate buffer; PBS-T, phosphate buffered saline with 0.2% Triton 
X-100; PD, Parkinson’s disease; PEG, polyethylenglycol; RT, room temperature; SNpc, 
substantia nigra pars compacta; TH, tyrosine hydroxylase; WT, wild type; 4HNE, 
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Page 3 
Abstract 
Parkinson’s disease (PD) is a neurodegenerative disease with motor symptoms as well as 
non-motor symptoms that precede the onset of motor symptoms. Mitochondrial complex I 
inhibitor, rotenone, has been widely used to reproduce PD pathology in the central nervous 
system (CNS) and enteric nervous system (ENS). We reported previously that 
metallothioneins (MTs) released from astrocytes can protect dopaminergic neurons against 
oxidative stress. The present study examined the changes in MT expression by chronic 
systemic rotenone administration in the striatum and colonic myenteric plexus of C57BL 
mice. In addition, we investigated the effects of MT depletion on rotenone-induced 
neurodegeneration in CNS and ENS using MT-1 and MT-2 knockout (MT KO) mice, or using 
primary cultured neurons from MT KO mice. In normal C57BL mice, subcutaneous 
administration of rotenone for 6 weeks caused neurodegeneration, increased MT expression 
with astrocytes activation in the striatum and myenteric plexus. MT KO mice showed more 
severe myenteric neuronal damage by rotenone administration after 4 weeks than wild-type 
(WT) mice, accompanied by reduced astroglial activation. In primary cultured mesencephalic 
neurons from MT KO mice, rotenone exposure induced neurotoxicity in dopaminergic 
neurons, which was complemented by addition of recombinant protein. The present results 
suggest that MT seems to provide protection against neurodegeneration in ENS of 
rotenone-induced PD model mice.  
 
Key Words: Parkinson’s disease; rotenone; enteric nervous system; astrocytes; 
metallothionein 
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Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disease with motor symptoms, 
such as tremor, bradykinesia, rigidity, and postural instability that are based on selective loss 
of nigrostriatal dopaminenergic neurons, and with non-motor symptoms such as dysosmia, 
orthostatic hypotension and constipation. Lewy-bodies (LBs) and Lewy-neurites (LNs) are 
pathological hallmarks of PD, which are cytoplasmic inclusions of insoluble, aggregated 
proteins, including major component α-synuclein (Spillantini et al. 1997). Braak et al. and 
other groups reported that LBs and LNs exist in not only the nigrostriatal pathway, but also 
the olfactory bulb in the central nervous system (CNS), dorsal motor nucleus of the vagus, 
cardiac sympathetic nerves and myenteric neurons in the enteric nervous system (ENS) 
(Braak et al. 2003; Hubbard et al. 2007; Orimo et al. 2008).  
Although the pathogenic mechanisms of PD remain to be elucidated, evidence 
suggests the involvement of mitochondrial dysfunction and oxidative stress in the substantia 
nigra (Parker et al. 1989; Schapira et al. 1989; Sofic et al. 1992). Rural life, agricultural work 
life and exposure to pesticides are possible environmental risk factors for PD (Wong et al. 
1991; Tanner et al. 2011). Rotenone is a natural pesticide, a mitochondrial complex I inhibitor, 
and previous reports indicated that users of rotenone or agricultural workers were at higher 
risk of PD and associated gastrointestinal neuropathology (Dhillon et al. 2008). Previous 
experimental studies have demonstrated that long-term systemic administration of rotenone in 
rats produced many features of PD pathology. For example, Betarbet et al. reported that 
long-term systemic administration of rotenone in Lewis rats replicated the hallmarks of PD, 
including selective nigrostriatal dopaminergic neurodegeneration, formation of LBs in the 
substantia nigra and parkinsonian motor dysfunction (Betarbet et al. 2000). In addition, 
long-term treatment with rotenone caused gastrointestinal dysfunction in rats (Greene et al. 
2009). Direct intragastric administration of rotenone in mice resulted in accumulation and 
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aggregation of α-synuclein in neurons of the dorsal motor nucleus of the vagus and 
intermediolateral nucleus of the spinal cord, accompanied by neuronal loss and astrogliosis 
(Pan-Montojo et al. 2010). Thus, rotenone has been widely used to reproduce PD pathology 
in CNS and ENS.  
Metallothioneins (MTs) are a family of low-molecular weight, cysteine-rich and 
inducible intracellular proteins, and are known to be involved in homeostasis and 
detoxification of heavy metals and scavenging of free radicals. MTs have neuroprotective 
effects in various neurological disorders of both the CNS and ENS (Stankovic et al. 2007; 
Pedersen et al. 2009). We have previously demonstrated that MT-1 and MT-2 have 
neuroprotective roles against dopaminergic neuronal damage in an animal model of PD 
(Asanuma et al. 2002) and that MTs released from astrocytes is a potent protector of 
dopaminergic neurons against oxidative stress (Miyazaki et al. 2011; 2013). Up-regulation of 
MT expression in reactive astrocytes has been reported in the substantia nigra of PD patients, 
suggesting the involvement of astrocytes in mediating the neuroprotective effects of MTs 
(Michael et al. 2011).  
The present study was designed to elucidate the MT expression after long-term 
subcutaneous administration of rotenone in CNS and ENS of C57BL mice. We also 
investigated the role of MT in the rotenone-induced pathological changes in ENS using MT 
knockout (KO) mice, and the neuroprotective effect of MT using primary cultured neurons.  
 
Materials and Methods  
Animals  
Male C57BL/6J mice weighting 20-25 g (9-week-old) were purchased from Japan Charles 
River Laboratories Japan, Inc. (Yokohama, Japan). Male homozygous MT-1 and MT-2 
knockout (MT KO) mice with simultaneous disruption of both MT-1 and MT-2 genes 
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(Masters et al., 1994) were purchased from the Jackson Laboratories (#2211: 
129S7/SvEvBrd-MT1
tm1Bri
MT2
tm1Bri
/J; Bar Harbor, ME). The 129/Sv mice were employed as 
WT controls, since the MT KO mice were raised on a 129/Sv genetic background. The 
animals were acclimated to and maintained at 23°C under a 12-h light/dark cycle (lights on 
08:00-20:00 h). Mice were housed in standard laboratory cages and had free access to food 
and water throughout the study period. All animal procedures were in strict accordance with 
the NIH Guide for the Care and Use of Experimental Animals and the Guideline for Animal 
Experiments of Okayama University Advanced Science Research Center, and were approved 
by the Animal Care and Use Committee of Okayama University Advanced Science Research 
Center. Special interest was taken to minimize the number of animals used in this research. 
 
Administration of Rotenone  
Rotenone (Sigma, St. Louis, MO) was dissolved in vehicle solution [dimethylsulphoxide 
(DMSO) and polyethylenglycol (PEG) (1:1)], and then poured into the tank of an osmotic 
mini pump (Alzet, #2004; Durect Corporation, Cupertino, CA). Mice (9-week-old) were 
anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and the osmotic pump was implanted 
under the skin of the back. The dose of infused rotenone was 50 mg/kg/day calculated by 
average body weight and at a delivery rate of 0.25 μl/h. For the control group, the same 
volume of vehicle (DMSO:PEG = 1:1) was infused using the subcutaneously implanted 
osmotic pump. 
 
Body Weight and Behavioral Test 
Spontaneous locomotor activity was observed in a circular open field measuring 60-cm in 
diameter with a surrounding 50-cm high wall. The bottom was divided into two equal 
concentric zones with 18 areas of equal extension. Each animal was placed in the middle of 
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the openfield at daytime every week after pump implantation, and then the number of line 
crossing per 3 min were counted. All observations were performed during the daytime within 
the same time (15:00-17:00 h). 
 
Tissue Collection and Preparation 
After the experimental period, mice were deeply anesthetized with sodium pentobarbital (80 
mg/kg, i.p.) and perfused intracardially with ice-cold saline. The brain and the colon were 
rapidly removed and post-fixed in a Histochoice Tissue Fixative (Sigma) overnight at 4°C. 
The brains were cryoprotected in 15% sucrose in 0.1 M sodium phosphate buffer (PB; pH 
7.4) with 0.1% sodium azide, and then coronal frozen sections (20-μm-thick) were prepared 
at levels containing the substantia nigra pars compacta (SNpc: -2.8 to -3.0 mm from the 
bregma) or the mid-striatum (+0.6 to +1.0 mm from the bregma) using a cryostat. The 
ascending colon samples were rinsed briefly in saline, dehydrated, and embedded in paraffin. 
The paraffin-embedded tissue sections were cut (4-μm-thick) by a microtome. 
 
Immunohistochemistry of Mouse Tissue Sections 
The brain sections were soaked in 0.5% hydrogen peroxide in 10 mM phosphate buffered 
saline with 0.2% Triton X-100 (PBS-T), followed by incubation in 1% normal goat serum for 
30 min at room temperature (RT). Then, they were reacted with rabbit anti-tyrosine 
hydroxylase (TH; dilution 1:1000; Chemicon International, Temecula, CA) or rat 
anti-dopamine transporter (DAT; 1:1000; Chemicon International) overnight at 4°C. After 
extensive rinsing in PBS-T, the sections were reacted with goat biotinylated anti-rabbit IgG 
secondary antibody (1:500; Vector Laboratories, Burlingame, CA) or rabbit biotinylated 
anti-rat IgG secondary antibody (1:1000; Vector Laboratories) for 2 h at RT, and then 
incubated with avidin-biotin peroxidase complex (1:1000, Vector Laboratories) for 1 h at RT. 
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For visualizing of TH-immunopositive cells, the sections were soaked in a solution 
containing 3,3’-diaminobenzidine, nickel, and hydrogen peroxide.  
For immunofluorescence staining, the brain sections were placed in 1% normal goat 
serum for 30 min at RT, and then incubated with rabbit anti-glial fibrillary acidic protein 
(GFAP) polyclonal antibody (1:1000; Dako Cytomation, Glostrup, Denmark) and mouse 
anti-MT (1:100; Dako Cytomation) overnight at 4°C. The sections were incubated for 2 h at 
RT with goat anti-rabbit IgG conjugated to Alexa Fluor 488 (1:1000; Molecular Probes, 
Eugene, OR) and goat anti-mouse IgG conjugated to Alexa Fluor 594 (1:1000; Molecular 
Probes). 
For immunostaining of colonic sections, the sections were deparaffinized, and then 
activated by autoclave for 5 min at 120°C. After return to RT, the sections were placed in 
10% normal goat serum or donkey serum for 10 min, and then incubated overnight with 
primary antibody of rabbit anti-TH (1:200; Millipore, Temecula, CA), mouse anti-HuC/D (10 
μg/ml; Molecular Probes), rabbit anti-β-tubulin (1:200; GeneTex, Tokyo, Japan), goat 
anti-choline acetyltransferase (ChAT; 1:200; Chemicon International), rabbit anti-GFAP 
(1:200; Dako Cytomation), mouse anti-GFAP (1:200; Millipore), goat anti-GFAP (1:200; 
Abcam), rabbit anti-MT (1:200; Santa Cruz Biotechnology, Santa Cruz, CA), or goat 
anti-4-hydroxynonenal (4HNE; 1:200; Abcam, Cambridge, UK) polyclonal antibody at 4°C. 
The sections were incubated with goat anti-mouse IgG conjugated to Alexa Fluor 594 or 
Alexa Fluor 488, goat anti-rabbit IgG conjugated to Alexa Fluor 488 or donkey anti-goat IgG 
conjugated to Alexa Fluor 594 (1:200; Molecular Probes) for 30 min at RT. 
 
Primary Culture of Neurons 
Primary cultured neurons were prepared from the mesencephalon of MT KO mice embryos at 
15 days. The cells from the mesencephalon were plated in Dulbecco's modified Eagle's 
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medium (Invitrogen, San Diego, CA) containing 10% fetal bovine serum at a density of 2 × 
10
5
 cells/cm
2
 in 4-chamber culture slides coated with poly-D-lysine (Becton Dickinson 
Labware, Franklin Lakes, NJ). Within 24 h after initial plating, the medium was replaced with 
fresh medium supplemented with 2 μM cytosine-β-D-arabinofuranoside to inhibit the 
replication of non-neuronal cells, followed by incubation for a further 7 days. In neuron-rich 
cultures, 95% of the cells were immunoreactive for the neuronal marker 
microtubule-associated protein 2.  
 
Cell Treatments 
To identify whether MT can protect dopaminergic neurons against rotenone-induced 
neurotoxicity, the primary cultured mesencephalic neurons from MT KO mice were treated 
with rotenone (final concentration 5 nM) and rabbit MT-1 recombinant protein (final 
concentration 25 ng/ml; ENZO Life Sciences, Farmingdale, NY) for 24 h. 
 
Immunocytochemistry of Primary Cultured Neurons  
The cells on the chamber slides were fixed with 4% paraformaldehyde for 20 min, blocked 
with 2.5% normal goat serum for 20 min, and reacted with mouse anti-TH (1:1000; 
Millipore) for 18 h at 4°C. The secondary antibodies used were goat anti-mouse IgG 
conjugated to Alexa Fluor 594. The cells were counterstained with Hoechst nuclear stain (10 
μg/ml) for 2 min and washed before mounting with Fluoromounting medium (Dako 
Cytomation).  
 
Image Analysis 
The number of TH-immunopositive neurons in the SNpc of a midbrain section (-2.8 to -3.0 
mm from the bregma) was counted and TH or DAT-immunoreactivity in the mid-striatum 
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(+0.6 to +1.0 mm from the bregma) were measured using a microscope and an image analysis 
system (NIH Image J 1.44K, Bethesda, MD) at x200 or x40 magnification, respectively. The 
boundary between the substantia nigra pars compacta and ventral tegmental area was defined 
by a line extending dorsally from the most medial boundary of the cerebral peduncle. Striatal 
GFAP and MT-immunopositive astrocytes were counted using a fluorescence microscope at 
x200 magnification. In the brain sections, the number of immunopositive cells or the optical 
density of immunoreactivity from the left and right image was averaged for all sections 
analysed. The TH, GFAP, MT, HuC/D, β-tubulin, ChAT and 4HNE-immunoreactivity in the 
myenteric plexus of the colon (10-30 images/2 sections at different level/animal, 4-7 
animals/group) were observed using a fluorescence microscope at x400 magnification and 
quantified by NIH Image J 1.44K. The integrated density of each signal was calculated as 
follows: integrated density = (signal density in the myenteric plexus - background density in 
the adjacent muscle layer) x area of positive signal in the plexus. The number of 
HuC/D-immunopositive cells in the myenteric plexus of a colonic sections was counted using 
a fluorescence microscope at x400 magnification. All slides for immunofluorescence staining 
were analyzed under a fluorescence microscope. They were used a mercury lamp through a 
470-490 nm and 530-550 nm band-pass filters to excite Alexa Fluor 488 and Alexa Fluor 594, 
respectively. The light emitted from Alexa Fluor 488 and Alexa Fluor 594 was collected 
through 515-550 nm band-pass filters or 590 nm long-pass filters, respectively. 
TH-immunopositive cells on chamber slides were counted and were calculated in 10 to 12 
randomly chosen fields under the microscope. Counting was performed blindly.  
 
Statistical Analysis 
Values were expressed as mean±SEM. Differences among groups were examined by one-way 
analysis of variance (ANOVA) followed by post-hoc Tukey-test (J STAT software). A p value 
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less than 0.05 was considered statistically significant.  
 
Results 
Effects of Subcutaneous Rotenone administration on Spontaneous Locomotor Activity in 
C57BL Mice 
Subcutaneous administration of rotenone for up to 6 weeks had no effect on body weight of 
C57BL mice (Fig. 1a). While, it showed a significant decrease in spontaneous locomotor 
activity compared with vehicle-treated C57BL mice at 2, 5 and 6 weeks (Fig. 1b). 
 
Effects of Rotenone on Dopaminergic Neurons, Astrocytes and MT Expression in the Striatum 
We used TH-immunohistochemistry as a marker of dopaminergic neurons. Treatment with 
rotenone for 6 weeks decreased the optical density of striatal TH-immunoreactivity (Fig. 2a). 
In addition, the number of GFAP-positive astrocytes were increased (Fig. 2b) and 
MT-positive cells (Fig. 2c) tended to increase, and these signals were partly colocalized (Fig. 
2d) in the striatum at 6 week of subcutaneous rotenone administration.  
 
Effects of Rotenone on Myenteric Neurons, Glial Cells and MT Expression  
Administration of rotenone for 6 weeks resulted in decrease in TH-immunoreactive integrated 
density in the ascending colon of C57BL mice (Fig. 3a). Rotenone tended to increase 
GFAP-immunopositive integrated density in the myenteric plexus of the colon at 6 weeks 
(Fig. 3b). Treatment with rotenone for 6 weeks markedly increased MT-immunopositive 
integrated density in the myenteric plexus (Fig. 3c).  
 
Effects of Rotenone on Spontaneous Locomotor Activity in MT KO Mice 
Administration of rotenone for up to 4 weeks had no effect on body weight of WT 129/Sv 
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mice and MT KO mice with 129/Sv genetic background (Fig. 4a). Baseline of locomotor 
activity in vehicle-treated MT KO mice was higher than that in vehicle-treated WT controls 
(Fig. 4b), implying possible neurodevelopmental changes by MT deficiency. Unlike body 
weight, the rotenone-induced reduction of spontaneous locomotor activity was much greater 
in MT KO mice than that in WT 129/Sv mice (Fig. 4b). 
 
Effects of MT Depletion on Rotenone-induced Changes in Dopaminergic Neurons and 
Astrocytes in the Basal Ganglia 
Four-week administration of rotenone caused greater loss of striatal TH- and 
DAT-immunoreactivities of dopaminergic nerve fibers but not nigral TH-positive neurons in 
MT KO mice, compared with WT 129/Sv mice (Fig. 5a-c). Furthermore, 4-week 
administration of rotenone significantly increased the number of GFAP-positive astrocytes in 
the striatum of WT mice, but not in MT KO mice (Fig. 6a). Reflecting astrocyte activation, 
4-week administration of rotenone in WT mice increased the number of striatal MT-positive 
cells (Fig. 6b). Increased MT-positive signals were partly colocalized with GFAP-positive 
reactive astrocytes in the striatum of WT mice after rotenone administration (Fig. 6c).  
 
Effects of MT Depletion on Rotenone-induced Changes in Neurons and Glial Cells in ENS 
Administration of rotenone for 4 weeks significantly decreased the number of 
HuC/D-immunopositive neurons and reduced the integrated density of TH-immunopositive 
signals in colonic myenteric plexuses of WT mice (Fig. 7a and 7c). In addition, in MT KO 
mice, the rotenone exposure significantly reduced the integrated density of β-tubulin and 
ChAT-immunopositive signals in colonic myenteric plexuses (Fig. 7b and 7d) as well as the 
reductions of HuC/D-positive neurons and TH-positive signals. On the other hand, systemic 
rotenone administration also increased the integrated density of GFAP-immunoreactivity (Fig. 
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8a) and markedly up-regulated MT-immunoreactivity in the myenteric plexuses of WT mice 
(Fig. 8b). In contrast to the up-regulation of GFAP signals in WT mice, rotenone markedly 
reduced myenteric GFAP-immunoreactivity in MT KO mice (Fig. 8a). MT-immunopositive 
signals were colocalized with GFAP-immunopositive signals (Fig. 8c). We examined 
myenteric 4HNE-immunoreactivity as a marker of lipid peroxidation by rotenone-induced 
oxidative stress (Fig. 9a). Subcutaneous rotenone administration significantly increased the 
ratio of 4HNE to β-tubulin-immunopositive signal in the myenteric plexus in MT KO, 
compared with WT mice (Fig. 9b).  
 
Neuroprotective Effects of MT against Rotenone-induced Neurotoxicity in Primary Cultured 
Neurons  
In mesencephalic primary cultured neurons from MT KO mice, rotenone (5 nM) exposure 
significantly decreased the number of TH-positive dopaminergic neurons (Fig. 10). Treatment 
with MT-1 recombinant protein (5 ng/ml) could attenuate the rotenone-induced toxicity in 
neurons from MT KO mice.  
 
Discussion 
We examined the effects of long-term subcutaneous administration of rotenone on neurons, 
astroglial cells and MT expression in CNS and ENS in mice. The present study demonstrated 
that (1) long-term administration of rotenone markedly increased MT expression in the 
myenteric glial cells, (2) rotenone-induced neuronal loss in the myenteric plexus was more 
obvious in MT KO mice compared with WT mice, (3) rotenone exposure caused 
degeneration of primary cultured dopaminergic neurons from MT KO mice, which was 
attenuated by complement with MT protein.  
Several experimental models of PD induced by rotenone have been described 
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(Betarbet et al. 2000; Sherer et al. 2003; Fleming et al. 2004; Saravanan et al. 2005; Drolet et 
al. 2009; Greene et al. 2009). The findings in these models suggest that rotenone 
administration can reproduce several features of PD in both CNS and ENS. Previous studies 
reported that intragastric administration of rotenone caused accumulation of α-synuclein and 
PD-like pathology in ENS (Pan-Montojo et al. 2012). To rule out direct damage of the ENS 
by the toxin, rotenone was infused subcutaneously using an osmotic pump in the present 
study. At first, we examined MT expression by subcutaneous rotenone administration in CNS 
and ENS using C57BL mice. In CNS, administration of rotenone for 6 weeks caused 
significant degeneration of striatal dopaminergic nerve terminal and slight induction of MT. 
In ENS, rotenone induced significant neurodegeneration and remarkable up-regulation of MT 
expression in myenteric plexus. Neuronal and glial cells in ENS are generally exposed 
various environmental factors, such as dietary nutritional and bacterial inflammatory stimuli. 
Therefore, it is assumed that there is temporal difference of region-specific susceptibility to 
rotenone toxicity between CNS and ENS.  
Astrocytes are abundant in CNS and play various roles to support neurons, such as 
removal of neurotoxic molecules, synthesis of nutritional factors, constitution of blood brain 
barrier and production of antioxidants (Heneka et al. 2010). GFAP-positive activated 
astrocytes are seen in neurodegenerative disorders, suggesting the involvement of astrocytes 
in various neurodegenerative diseases including PD (Ishida et al. 2006; Durrenberger et al. 
2009). In fact, astrogliosis has been described in the brain of PD patients and rotenone-treated 
rats (Schwarz et al. 1996; Samantaray et al. 2007). Moreover, enteric astroglial cells which 
express GFAP also exist in ENS (Jessen and Mirsky 1983). It is also reported that enteric 
glial cells regulate tight-junction integrity and epithelial permeability at mucosal surfaces 
comparable with blood-brain barrier function (Savidge et al. 2007). Enteric glial cells also 
have been implicated in the regulation of barrier functions in health and disease conditions. 
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The present study demonstrated that administration of rotenone in C57BL mice tended to 
increase GFAP-positive glial cells in the colonic myenteric plexus, as well as in the striatum. 
This suggests the possible involvement of GFAP-positive activated glial cells in some 
reactions to the systemic rotenone-induced neurodegeneration in both CNS and ENS. 
MT-1 and MT-2 are cysteine-rich metal-binding proteins, which can exert high 
anti-oxidative activity by scavenging free radicals. MTs are up-regulated specifically in 
astrocytes in response to neuronal injury (Chung et al. 2004), and are localized in 
GFAP-positive astrocytes in ischemic lesions (Wakida et al. 2007). We have previously 
reported that MT-1 and MT-2 provide neuroprotection against 6-hydroxydopamine-induced 
nigrostriatal neurodegeneration (Asanuma et al. 2002) and against L-DOPA-induced 
dopamine quinone neurotoxicity in parkinsonian mice (Miyazaki et al. 2007), and recently 
found that MTs were induced and released in astrocytes, which protect dopaminergic neurons 
against oxidative stress (Miyazaki et al. 2011; 2013). In addition, MT transgenic mice were 
reported to be resistant to rotenone-induced neurotoxicity (Ebadi et al. 2005). Other studies 
demonstrated that mitochondrial oxidative stress specifically induced MTs than other 
antioxidants, and that MTs scavenged free radicals in mitochondria (Kondoh et al. 2001; 
Futakawa et al. 2006).  
In our study, 4-week administration of rotenone resulted in a significant decrease in 
the relative density of TH-immunoreactivity and increase in the number of GFAP-positive 
astrocytes in the striatum of WT 129/Sv mice. The same treatment also decreased number of 
HuC/D-positive cells and signals of TH or ChAT, and increased signal of GFAP in the colonic 
myenteric plexus. Furthermore, administration of rotenone markedly increased the number of 
MT-positive signals in the myenteric astroglial cells of WT mice. Compared with WT mice, 
MT depletion exacerbated subcutaneous rotenone infusion-induced neurodegeneration in 
ENS, coinciding with significant decrease in colonic GFAP-immunoreactivity. Moreover, 
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4HNE-immunoreactivity which is considered as an index of lipid peroxidation in the 
myenteric plexus was notably increased by rotenone administration in MT KO mice than WT 
mice. Besides, previous report demonstrated that 4HNE could induce MT transcription in 
astrocyte (Braithwaite et al. 2010). These results imply that rotenone-induced 
neurodegeneration accompanying enhancement of lipid peroxidation were aggravated by the 
deficiency of MT. Thus, it is assumed that MT in the myenteric astroglial cells could protect 
neurons against rotenone-induced neuronal damages by preventing oxidative stress. A 
previous in vitro study showed that MT can suppress not only oxidative stress, but also 
apoptosis and α-synuclein expression induced by rotenone exposure (Reinecke et al. 2006). 
However, further studies are needed to elucidate the neuroprotective profile of MT and 
myenteric astroglial cells in ENS, especially against long-term systemic administration of 
rotenone, by more quantitative analysis using whole-mount immunostaining. 
Although MT is predominately expressed and released in/from astrocytes, small 
amount of intrinsic MT is expressed even in neurons (Hidalgo J et al., 1994). Therefore, we 
examined role of MT in the rotenone-induced neurotoxicity. In the present study, primary 
cultured mesencephalic neurons from MT KO mice were more vulnerable to the rotenone 
toxicity than those from WT mice (data not shown). The rotenone-induced toxicity in neurons 
from MT KO mice was restored by replacement with MT. These results also suggest that MT 
protects neurons from rotenone-induced neurotoxicity. 
In conclusion, long-term subcutaneous systemic administration of rotenone caused not 
only myenteric neurodegeneration with marked expression of MT in the colon but not striatal 
dopaminergic neuronal damage. The toxin-induced myenteric neuronal damage was 
exacerbated by MT deficiency, accompanied with reduction in astroglial cells activation and 
enhancement of oxidative stress. These findings suggest that the neuronal damage in ENS 
induced by systemic administration of rotenone represents region-specific vulnerability to the 
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toxin. The findings also suggest that the expression of MT in astroglial cells protects 
myenteric neurons from rotenone-induced neuronal damage. Taken together with the 
neuroprotective effects of MT in striatal astrocytes described in previous studies (Miyazaki et 
al. 2011; 2013) and our culture study, therefore, MT seems to be a suitable target for 
neuroprotective strategies against pathologies affecting both the CNS and ENS in PD. 
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Figure legends 
 
Fig. 1 Effects of chronic subcutaneous administration of rotenone on body weight and 
behavioral activity in C57BL mice. Time-course changes in body weight (a) and spontaneous 
locomotor activity (b) in C57BL mice treated with rotenone (50 mg/kg/day) or vehicle. 
Values are mean±SEM (n=4-7). *p<0.05 vs. vehicle-treated group. 
 
Fig. 2 Effect of subcutaneous administration of rotenone on dopaminergic neurons, astrocytes 
and MT expression in the striatum of C57BL mice. Changes in the optical density of 
TH-immunoreactivity (a), and the number of GFAP-positive astrocytes (b) and MT-positive 
cells (c) in the mid-striatum (+0.6 to +1.0 mm from the bregma) after subcutaneous 
administration of rotenone (50 mg/kg/day) for 6 weeks. Partial colocalization of 
MT-immunopositive cells with GFAP-immunopositive astrocytes (d: green; GFAP, red; MT). 
Data are mean±SEM (n=4-5). *p<0.05 vs. vehicle-treated group. Scale bars = 500 μm (a); 50 
μm (b-d). 
 
Fig. 3 Effects of subcutaneous administration of rotenone on myenteric neurons, glial cells 
and MT expression in the colon of C57BL mice. Changes in integrated density of 
TH-positive neurons (a), GFAP-positive glial cells (b) and MT-positive signals (c) at 6 weeks 
after subcutaneous administration of rotenone (50 mg/kg/day). Data are mean±SEM (15-30 
images/2 slices/animal, 4-5 animals/group). **p<0.01 vs. vehicle-treated group. Scale bars = 
25 μm. 
 
Fig. 4 Effects of long-term subcutaneous administration of rotenone on body weight and 
behavioral activity in MT KO and WT mice. Time-course changes in body weight (a) and 
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spontaneous locomotor activity (b) in MT KO mice and WT 129/Sv mice treated with 
rotenone (50 mg/kg/day) or vehicle. Values are mean±SEM (n=4-7). *p<0.05 vs. 
vehicle-treated WT mice, ##p<0.01 vs. vehicle-treated MT KO mice. 
 
Fig. 5 Effects of subcutaneous administration of rotenone on nigrostriatal dopaminergic 
neurons in MT KO and WT mice. Changes in the number of TH-positive dopaminergic 
neurons in the substantia nigra (-2.8 to -3.0 mm from the bregma)(a), optical densities of 
TH-immunoreactivity (b) and optical density of DAT-immunoreactivity (c) in the 
mid-striatum (+0.6 to +1.0 mm from the bregma) at 4 weeks after rotenone administration 
(50 mg/kg/day). Data are mean±SEM (n=4-7). *p<0.05, **p<0.01 between two indicated 
groups. Scale bars = 100 μm (a); 500 μm (b, c). 
 
Fig. 6 Effects of subcutaneous administration of rotenone on striatal astrocytes and MT 
expression in MT KO and WT mice. Changes in the number of GFAP-positive astrocytes (a: 
green) and MT-immunopositive cells (b: red) in the mid-striatum at 4 weeks after chronic 
rotenone infusion (50 mg/kg/day). Partial colocalization of MT-immunopositive cells and 
GFAP-immunopositive astrocytes (c: green; GFAP, red; MT). Data are mean±SEM (n=4-7). 
*p<0.05, **p<0.01 between two indicated groups. Scale bars = 50 μm. 
 
Fig. 7 Effects of subcutaneous administration of rotenone on myenteric neurons in colon of 
MT KO and WT mice. Changes in the number of HuC/D-positive cells (a: red) and the 
integrated density of β-tubulin-positive neurons (b: green), TH-positive neurons (c: green), 
and ChAT-positive neurons (d: red) in the myenteric plexus of ascending colon at 4 weeks 
after administration of rotenone (50 mg/kg/day). Data are mean±SEM (10-30 images/2 
slices/animal, 4-7 animals/group). *p<0.05, **p<0.01 between two indicated groups. Scale 
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bars = 25 μm. 
 
Fig. 8 Effects of subcutaneous administration of rotenone on myenteric glial cells and MT 
expression in colon of MT KO and WT. Changes in the integrated density of GFAP-positive 
myenteric glial cells (a: red) and MT-immunoreactivity (b: green) in the myenteric plexus of 
ascending colon at 4 weeks after administration of rotenone (50 mg/kg/day). Colocalization 
of MT-immunopositive cells with GFAP-immunopositive astrocytes (c: red; GFAP, green; 
MT). Data are mean±SEM (10-30 images/2 slices/animal, 4-7 animals/group). *p<0.05 
between two indicated groups. Scale bars = 25 μm. 
 
Fig. 9 Lipid peroxidation in myenteric neurons induced by subcutaneous rotenone infusion. 
Representative images of 4HNE-immunoreactivity (a: red), double staining of 4HNE and 
β-tubulin (b: red, 4HNE; green, β-tubulin) and changes in ratio of integrated density of 4HNE 
to β-tubulin-immunopositive signals in the myenteric plexus of ascending colon at 4 weeks 
after administration of rotenone (50 mg/kg/day). Data are mean±SEM (10-30 images/2 
slices/animal, 4-7 animals/group). *p<0.05, **p<0.01 between two indicated groups. Scale 
bars = 25 μm. 
 
Fig. 10 Neuroprotective effects of MT against rotenone-induced neurotoxicity in primary 
cultured mesencephalic neurons. Cell viability of TH-positive dopaminergic neurons in 
mesencephalic culture from MT KO mice at 24 h after rotenone exposure (5 nM) 
with/without MT-1 recombinant protein (25 ng/ml). Data are mean±SEM (n=3-4). †p< 0.001 
vs. control, §p< 0.001 vs. rotenone-treated group.  
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